P. Weiden and W. Glazer, Assessment and treatment selection for « revolving door » inpatients with schizophrenia, Psychiatr Q, vol.68, issue.4, pp.377-92, 1997.

E. Lindstrom and K. Bingefors, Patient compliance with drug therapy in schizophrenia: economic and clinical issues, Pharmacoeconomics, vol.18, pp.105-129, 2000.

J. A. Lieberman, T. S. Stroup, and J. P. Mcevoy, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, vol.353, issue.12, pp.1209-1232, 2005.

P. Weiden and M. Olfson, Cost of relapse in schizophrenia, Schizophrenia Bulletin, vol.21, pp.419-448, 1995.

D. Robinson, M. G. Woerner, and J. M. Alvir, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch Gen Psychiatry, vol.56, issue.3, pp.241-288, 1999.

D. Misdrahi, L'observance thérapeutique : un objectif essentiel, L'Encéphale, vol.32, pp.1076-1085, 2006.
DOI : 10.1016/s0013-7006(06)72689-6

L. Samalin, M. Abbar, and P. Courtet, Recommandations Formalisées d'Experts de l'AFPBN : prescription des neuroleptiques et antipsychotiques d'action prolongée, L'Encéphale, vol.39, pp.189-203, 2013.
DOI : 10.1016/s0013-7006(13)70121-0

S. Heres, M. Lambert, and R. Vauth, Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics, Eur Psychiatry, vol.29, pp.1409-1422, 2014.

S. M. Stahl, Long-acting injectable antipsychotics: shall the last be first?, CNS Spectr, vol.19, issue.1, pp.3-5, 2014.
DOI : 10.1017/s1092852913001016

J. Lauriello, T. Lambert, and S. Andersen, An 8-week, double-blind, randomized, placebocontrolled study of olanzapine long-acting injection in acutely ill patients with schizophrenia, J Clin Psychiatry, vol.69, issue.5, pp.790-799, 2008.

J. M. Kane, H. C. Detke, and D. Naber, Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia, Am J Psychiatry, vol.167, issue.2, pp.181-190, 2010.

D. P. Mcdonnell, J. Landry, and H. C. Detke, Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, singlearm, open-label study, Int Clin Psychopharmacol, vol.29, issue.6, pp.322-353, 2014.

, Décret n° 2012-1116 du 2 octobre 2012 relatif aux missions médico-économiques de la Haute Autorité de santé, 2012.

J. M. Kane, T. Kishimoto, and C. U. Correll, Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry, J Clin Epidemiol, vol.66, issue.8, pp.37-41, 2013.

T. Kishimoto, M. Nitta, and M. Borenstein, Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies, J Clin Psychiatry, vol.74, issue.10, pp.957-65, 2013.

D. De-graeve, A. Smet, and A. Mehnert, Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis, PharmacoEconomics, vol.23, pp.35-47, 2005.

P. M. Llorca, H. Miadi-fargier, and C. Lançon, Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation, L'Encéphale, vol.31, issue.2, pp.235-281, 2005.

G. Laux, B. Heeg, V. Hout, and B. , Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany, PharmacoEconomics, vol.23, pp.49-61, 2005.

J. M. Olivares, A. Rodriguez-martinez, and J. A. Burón, Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12-and 24-month follow-up from the e-STAR database in Spain, Appl Health Econ Health Policy, vol.6, issue.1, pp.41-53, 2008.

D. Wu, E. Lee, and W. S. Chung, Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: An approach using generalised estimating equations, Psychiatry Res, vol.210, issue.3, pp.745-50, 2013.

D. Taylor, C. Fischetti, and A. Sparshatt, Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use, Acta Psychiatr Scand, vol.120, issue.2, pp.97-101, 2009.

C. Carswell, D. A. Wheeler, and J. Vanderpyl, Comparative Effectiveness of Long-Acting Risperidone in New Zealand, Clin Drug Investig, vol.30, issue.11, pp.777-87, 2012.

F. Zhang, T. Si, and C. Chiou, Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia, Neuropsychiatric Disease and Treatment, vol.11, pp.657-68, 2015.

J. M. Kane, C. Zhao, and B. R. Johnson, Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly: final efficacy analysis, J Med Econ, vol.18, pp.145-54, 2015.

V. Lerner, High-dose olanzapine for treatment-refractory schizophrenia, Clin Neuropharmacol, vol.26, issue.2, pp.58-61, 2003.
DOI : 10.1097/00002826-200303000-00003

S. F. Qadri, P. R. Padala, and J. C. Strunk, High-Dose Olanzapine Orally Disintegrating Tablets for Treatment-Resistant Psychosis, Prim Care Companion J Clin Psychiatry, vol.8, issue.4, pp.244-245, 2006.
DOI : 10.4088/pcc.v08n0410a
URL : http://europepmc.org/articles/pmc1557475?pdf=render

J. M. Batail, S. Bleher, and C. Lozachmeur, Very-high-dose olanzapine for treatment-resistant schizophrenia, Open J Psychiatry, vol.2, pp.269-71, 2012.
DOI : 10.4236/ojpsych.2012.24037
URL : https://doi.org/10.4236/ojpsych.2012.24037

S. Raymond, M. Martin, and C. Netillard, Schizophrénie: évaluation du coût de la prise en charge, J Econ Medicale, vol.27, issue.7-8, pp.421-454, 2009.

M. Woronoff-lemsi, S. Limat, and M. Husson, Approche pharmaco-économique : évaluation pharmao-médico-économique de stratégies thérapeutiques : éléments de méthodologie, Doss. CNHIM, pp.40-51, 2000.

S. A. Kamat, S. Offord, and J. Docherty, Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients, Drugs in Context, vol.4, pp.212-67, 2015.